Conference abstract · 16 Oct 2017
Conference abstractPublished 26 Apr 2018
Technical challenges in developing biosimilar antibodies
Bioceros, Netherlands Polpharma Biologics, Poland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Since originator recombinant proteins are getting off patent, biosimilar molecules are entering the market. Although the overall costs of bringing a biosimilar product to the market is in general much lower than for an originator, the technical challenges to reach biosimilarity compared to originator product are significant. There is also a strong push to bring down the cost of goods to manufacture these products. Strategies will be presented to reach technical proof of similarity of specific antibodies while reducing production costs. These include innovative concepts to increase antibody titers on our CHOBCÃ?® platform using our SPOTâÂ?¢ technology and our USP toolbox to modulate relevant post-translational modifications like glycosylation and charge variants. In addition, these include, selection of new Protein A resins to decrease cost of goods while maintaining product quality, the development of high throughput methods, including Multi-Attribute Methods (MAM), to increase efficiency, and the extensive characterization of antibody charge variants (eg oxidation, deamidation, fucosylation, lysine truncation etc.) and disulfide linkage analysis to increase product knowledge. Recent Publications 1. Van Corven E (2014) Recombinant protein and mAb biopharmaceuticals to become a commodity? Pharmaceutical Bioprocessing. 2(2):107-109
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 23 Sep 2013
Cell culture process development of a biosimilar monoclonal antibody-Case study
Conference abstract · 18 Mar 2019
Recommendations for the development and validation of neutralizing antibody assays in support of biosimilar assessment
Conference abstract · 27 Jun 2016
Cell line development for the production of biosimilar monoclonal antibodies with high target bioactivity and high productivity
Conference abstract · 19 Oct 2016
Operational and technical challenges for drug development, scale up, scale down and higher scale manufacturing of biosimilars
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Emile Van Corven”

